Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Cancer Immunol Res. 2014 Aug 12;2(10):949–961. doi: 10.1158/2326-6066.CIR-14-0058

Figure 2. Study schema.

Figure 2

Patients received up to four vaccination cycles. Cyclophosphamide (CY) was given on day −1, and vaccine on day 0. Trastuzumab (T) was given weekly during active vaccine cycles, and timed to coincide with CY administration on day −1. During the interim period between cycles 3 and 4, trastuzumab could be given weekly or every 3 weeks as per the standard of care. GM-CSF levels and immunity were measured as indicated. CY=cyclophosphamide; T=trastuzumab; DTH=delayed-type hypersensitivity to HER-2-derived peptides. Skin biopsies on days +3 and +7 were from the largest vaccine site.